Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17562268 | 0.81 | MEN1 (0.34) | MEN1KMT2AL3MBTL1POLBNPC1 | |
| SCHEMBL753246 | 0.80 | MEN1 (0.59) | MEN1KMT2AL3MBTL1POLBBCAT2 | |
| SCHEMBL10134383 | 0.80 | MEN1 (0.83) | MEN1KMT2APOLBNPSR1BCAT2 | |
| SCHEMBL13745349 | 0.77 | KMT2A (0.51) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4797272 | 0.77 | MEN1 (0.59) | MEN1KMT2APOLBBCAT2MAPT | |
| SCHEMBL4797268 | 0.77 | MEN1 (0.59) | MEN1KMT2AL3MBTL1NPSR1BCAT2 | |
| SCHEMBL851116 | 0.77 | MEN1 (0.59) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL753331 | 0.76 | BCAT2 (0.60) | MEN1KMT2AL3MBTL1NPSR1BCAT2 | |
| SCHEMBL20176871 | 0.74 | MEN1 (0.55) | MEN1KMT2AL3MBTL1NPSR1BCAT2 | |
| SCHEMBL8736571 | 0.74 | MEN1 (0.55) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009111501-A1 | DERIVATIVES OF IMIDAZO [4, 5-D] PYRIDAZINE AND THEIR USE AS ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | MAVS, SARS1, HAVCR2 | MEN1 3857/4885KMT2A 4655/4885L3MBTL1 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.